StockpollyBeta
Get App
Popularity #1,120
XRAY · NASDAQ · Medical - Instruments & Supplies

Dentsply Sirona (XRAY)

Makes professional dental equipment, workflow software, consumables and continence-care devices.

$9.78
vs last close−0.18 (−1.76%)
Loading prices…

Something off on this page? Send us feedback.

DENTSPLY SIRONA Inc.XRAY
Health Care

Sells professional-dental equipment, workflow software and recurring consumables alongside implants, orthodontic appliances and continence-care devices. Revenue pairs connected capital equipment with recurring product sales and depends materially on distributors for dental consumable and equipment distribution.

Combines Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare. The range runs from imaging, scanners, treatment centers, CEREC CAD/CAM and workflow software to restorative and endodontic consumables, SureSmile aligners, implants and continence-care products. Sales reach dental professionals, laboratories, medical providers and patients in roughly 140 countries, with Europe the largest region and the United States its next-largest market.

Generates most revenue from manufactured devices, instruments and consumables, supplemented by digital-workflow software and services. Much of dental consumable and equipment volume moves through third-party distributors, while implants, endodontics and orthodontics also reach practitioners and labs directly. Demand for financed equipment and elective procedures, global device regulation and data requirements, a multi-year ERP rollout, and a manufacturing footprint spanning Europe and the United States are structural dependencies.

Company facts

CEODaniel T. Scavilla
ListedAug 12, 1987
ExchangeNASDAQ
HeadquartersCharlotte, NC
CountryUnited States
Employees14,000
CIK0000818479
ISINUS24906P1093

Market cap$1.99B
EPS (ttm)−$2.74
P/E (ttm)−3.63
ROE-39.8%
P/B1.48
P/S0.5471
Dividend yieldDiv yield4.82%
Beta1.24vs XLV 0.97

Price target$14.00+40.7%Average of 32 analysts
ConsensusHold19 of 32 analysts
Ratings

Target rangeAs of Sep 22, 2026

Latest analyst notes

DateFirmActionPriorCurrent
Sep 17, 2026BMO CapitalReiterate
Rating: —Target: $13
Rating: Market PerformTarget: $10
Aug 24, 2026BarclaysReiterate
Rating: —Target: $9
Rating: UnderweightTarget: $11
Aug 10, 2026BarringtonTarget
Target: $18
Target: $15
Aug 7, 2026BMO CapitalReiterate
Rating: —Target: $12
Rating: Market PerformTarget: $13
Jul 29, 2026Piper SandlerReiterate
Rating: —Target: $32
Rating: NeutralTarget: $14

Next report
Nov 5, 26
in 43 days
EPS estimate
$0.30
Revenue estimate
$865.7M
Fiscal quarter
Q3 FY26

EPSReportedEstimate

Feb '25May '25Aug '25Nov '25Feb '26May '26Aug '26Nov '26
Reported$0.26$0.43$0.52$0.37$0.27$0.27$0.52Pending
Estimate$0.47$0.29$0.50$0.45$0.28$0.28$0.35$0.30
Surprise−44.7%+48.3%+4.0%−17.8%−3.6%−3.6%+49.4%—

RevenueReportedEstimate

Feb '25May '25Aug '25Nov '25Feb '26May '26Aug '26Nov '26
Reported$905.0M$879.0M$936.0M$904.0M$961.0M$880.0M$898.0MPending
Estimate$901.3M$920.2M$904.6M$927.1M$926.2M$841.8M$889.9M$865.7M
Surprise+0.4%−4.5%+3.5%−2.5%+3.8%+4.5%+0.9%—
Estimate$0.30
ReportedDue Nov 5, 2026
Estimate$865.7M
ReportedDue Nov 5, 2026
View details

Debt to equity171.10%
Current ratio162.70%

ProfitabilityRevenueNet incomeNet margin

Q3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26
Revenue$951.0M$905.0M$879.0M$936.0M$904.0M$961.0M$880.0M$898.0M
Net income−$494.0M−$430.0M$20.0M−$45.0M−$427.0M−$146.0M−$10.0M$37.0M
Net margin0.0%0.0%2.3%0.0%0.0%0.0%0.0%4.1%

GrowthOperating income

Q3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26
Operating income−$462.0M−$509.0M$63.0M−$128.0M$46.0M$268.0M$30.0M$82.0M
YoY growthLoss widenedTurned loss+50.0%Turned lossTurned profitTurned profit−52.4%Turned profit

Balance sheet, Jun 30, 2026Cash & short-term investments $239.0M · Total debt $2.31B · Total assets $5.20B · Shareholders' equity $1.35B

Revenue
$898.0M
Operating income
$82.0M
Net income
$37.0M
View details

Dividend yield
4.82%
Next ex-date
—
Annual dividend
$0.48
per share
Schedule
Quarterly
4 payments a year

HistoryDividendAnnual yield

Mar '24Jun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25
Dividend$0.16$0.16$0.16$0.16$0.16$0.16$0.16$0.16
Annual yield1.74%2.41%2.29%3.38%4.29%4.02%5.12%5.56%
Ex-dateMar 27Jun 28Sep 27Dec 27Mar 28Jun 27Sep 26Dec 26
Payment dateApr 12Jul 12Oct 11Jan 10Apr 11Jul 11Oct 10Jan 9
View details

Institutions114.54%228.34M shares
387 holders · as of Jun 30, 2026
Insiders0.93%1.86M shares
25 holders · as of Aug 12, 2026
Adds to115.47%

199.35M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing

These groups come from separate filings that can overlap, so they add to 115.47%; nothing is left for Other.

Top shareholders13F · 13D/G · Form 4

HolderStakeSharesDate
BlackRock, Inc.Institution
13.40%26.71Mas of Jun 30, 2026
Generation Investment Management LLPInstitution
10.88%21.70Mfiled Feb 14, 2019
Veritas Asset Management LLPInstitution
6.76%13.47Mfiled Feb 6, 2019
Fuller & Thaler Asset Management, Inc.Institution
6.37%12.70Mas of Jun 30, 2026
Nuance Investments LLCInstitution
6.34%12.64Mfiled Feb 8, 2023

Insider tradesForm 4

DateInsiderRoleSharesAvg price
Jun 12, 2026Jonathan Jay Mazelskydirector+10,000$10.14
Jun 15, 2026Clyde Hoseindirector+6,500$9.99
Jun 11, 2026Michael J. Barberdirector+15,175$9.89
Jun 11, 2026Betsy D. Holdendirector+10,086$9.88
Jun 15, 2026Brian T. Gladdendirector+9,985$10.02
View details

  • Envista

    Dental portfolio overlaps imaging, consumables, implants, and orthodontics.

  • Align Technology

    Clear aligners and digital scanners target orthodontic and GP dentists.

  • Solventum

    Dental materials and orthodontics overlap core consumables.

Compare

CompanyPriceChange
Dentsply Sirona$9.78−1.76%$1.99B—6.70.5−4.1%
Envista$24.08−0.41%$3.93B41.715.31.4+7.1%
Align Technology$151.54−1.14%$10.98B26.612.82.7+4.3%
Solventum$88.57−0.21%$15.37B10.813.01.8+2.2%
Median26.613.01.8+4.3%